Table 2.
Esaxerenone treatment and use of add-on antihypertensives from week 12 onwards (full analysis set)
| Esaxerenone | ||||
|---|---|---|---|---|
| Monotherapy (n = 245) | + CCB (n = 59) | + RAS inhibitor (n = 64) | Total (N = 368) | |
| Duration groups of esaxerenone treatment, n (%)a | ||||
| 28 weeks group | 143 (58.4) | 35 (59.3) | 43 (67.2) | 221 (60.1) |
| 52 weeks group | 102 (41.6) | 24 (40.7) | 21 (32.8) | 147 (39.9) |
| Esaxerenone dosage at week 12, n (%) | ||||
| 2.5 mg/day | 82 (33.5) | 19 (32.2) | 28 (43.8) | 129 (35.1) |
| 5 mg/day | 157 (64.1) | 40 (67.8) | 36 (56.3) | 233 (63.3) |
| Esaxerenone dosage at last treatment, n (%) | ||||
| 2.5 mg/day | 62 (25.3) | 17 (28.8) | 25 (39.1) | 104 (28.3) |
| 5 mg/day | 183 (74.7) | 42 (71.2) | 39 (60.9) | 264 (71.7) |
| Add-on antihypertensive drug from week 12b, n (%) | 89 (36.3) | 10 (16.9) | 16 (25.0) | 115 (31.3) |
| CCB | 76 (31.0) | 1 (1.7) | 16 (25.0) | 93 (25.3) |
| Thiazide diuretic | 1 (0.4) | 0 (0.0) | 0 (0.0) | 1 (0.3) |
| RAS inhibitor | 9 (3.7) | 9 (15.3) | 0 (0.0) | 18 (4.9) |
| Other | 3 (1.2) | 0 (0.0) | 0 (0.0) | 3 (0.8) |
CCB calcium channel blocker, RAS renin–angiotensin system
aAll 368 patients received esaxerenone until week 28
bExcept for the baseline CCB or RAS inhibitor